BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.
2025
Research spotlight: Improving Predictions about brain cancer Outcomes with the right imaging criteria
Our study examines how different imaging criteria can be used to assess brain tumor responses in patients with melanoma treated with immunotherapy drugs. We identified one imaging method that was more accurate in predicting survival compared to others. While further work is needed, our study is promising and highlights the importance of more consistent imaging standards in clinical trials.
Sunbed Ban Anniversary: No Tan Worth Dying For
This January marks the 10th anniversary of the commercial solarium ban in Australia, however, data shows many Australians are still suntanning and have poor sun protection behaviours. Commercial solariums, also known as sunbeds or tanning beds, are classified by International Agency for Research on Cancer (IARC) in the highest risk category, Group 1: carcinogenic to humans.
Continuing Melanoma Research: Why, How,What?
Hello, everybody. It’s a pleasure for me to be here today and to have the chance to collaborate with Medscape in this quite interesting series about melanoma. For this first video, I want to introduce myself and let you know a little bit about my passion for melanoma investigation, and also why this is important to continue speaking about in the next couple of years.